Smithkline Beecham Corporation

Boehringer Mannheim Pharmaceuticals Corporation

Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham

Boehringer Mannheim Pharmaceutical Corporation

Boehringer Mannheim Pharmaceutical Corporation-smithkline Beecham

Smithkline Beecham Corporation Limited Prtnrshp No. 1

Eliot H Ohlstein

Giora Zeev Feuerstein

Tian-Li Yue

A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine

A new use of, and method of treatment of atherosclerosis using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine

The present invention provides a new medical use of the hydroxycarbazole compounds of Formula (I), preferably the hydroxylated metabolites of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol)(carve dilol), for inhibiting the migration and proliferation of smooth muscle cells. In particular, the present invention provides a new use for the hydroxycarbazole compounds of Formula (I) for prevention of restenosis following percutaneous transluminal coronary angioplasty (PTCA), suppression of the progression of vascular hypertrophy associated with hypertension, and prevention of development of atherosclerosis. ##STR1## wherein: R.sub.1 -R.sub.9 are independently --H or --OH, with the proviso that a at least one of R.sub.1 -R.sub.9 is OH.

Use of, and method of treatment using, hydroxycarbazole compounds for

Growing community of inventors

Glenmoore, PA, United States of America

Eliot H Ohlstein